- AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS
-
Compounds of the Formula (I), where W represents CH or N; and Q represents -CN, -C(=NOH)NH2, -CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson''s disease.
- -
-
Page/Page column 53
(2009/10/22)
-
- KINESIN INHIBITORS
-
This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder.
- -
-
-
- Composition of matter having bioactive properties
-
Particles of coordinated complex comprising a basic, hydrous polymer and a capacitance adding compound, as well as methods for their production, are described. These complexes exhibit a high degree of bioactivity making them suitable for a broad range of applications through their incorporation into conventional vehicles benefiting from antimicrobial and similar properties.
- -
-
-
- 3-Amino-2-quinoxalinecarbonitrile. New fused quinoxalines with potential cytotoxic activity
-
Starting with 3-amino-2-quinoxalinecarbonitrile 1,4-dioxide 1, a new series of quinoxaline derivatives was prepared through chemical modifications of the 2-cyano and 3-amino groups. Nitration of 3-amino-2-quinoxalinecarbonitrile 3 afforded the 7-nitro derivative 6. Diazotation of 3 gave the 3-chloro compound 9. 2,3-Quinoxalinedicarbonitrile 14 was obtained from 9. Pyridazino[4,5-b]quinoxalines 15 and 16 were prepared by condensing 14 with hydrazine hydrate. A triazolo[4,5-b]quinoxaline 18, a isothiazolo[4,5-b]quinoxaline 20 and two pyrazolo[3,4-b]quinoxalines 21 and 22 were identified. Compounds were tested as cytotoxic agents both in oxic and in hypoxic cells.
- Monge,Palop,Pinol,Martinez-Crespo,Narro,Gonzalez,Sainz,Lopez De Cerain,Hamilton,Barker
-
p. 1135 - 1139
(2007/10/02)
-